Teacher Retirement System of Texas raised its holdings in Iqvia Holdings Inc (NYSE:IQV) by 2.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 268,279 shares of the medical research company’s stock after buying an additional 5,561 shares during the period. Teacher Retirement System of Texas owned about 0.14% of Iqvia worth $31,166,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also added to or reduced their stakes in the company. FMR LLC increased its stake in shares of Iqvia by 41.1% in the fourth quarter. FMR LLC now owns 4,217,991 shares of the medical research company’s stock worth $490,004,000 after purchasing an additional 1,228,148 shares in the last quarter. Kentucky Retirement Systems bought a new stake in Iqvia during the fourth quarter valued at approximately $801,000. Kentucky Retirement Systems Insurance Trust Fund bought a new stake in Iqvia during the fourth quarter valued at approximately $364,000. CWM Advisors LLC lifted its position in Iqvia by 24.3% during the fourth quarter. CWM Advisors LLC now owns 2,971 shares of the medical research company’s stock valued at $345,000 after purchasing an additional 581 shares during the last quarter. Finally, Nordea Investment Management AB lifted its position in Iqvia by 15.9% during the fourth quarter. Nordea Investment Management AB now owns 414,995 shares of the medical research company’s stock valued at $48,209,000 after purchasing an additional 56,904 shares during the last quarter. 91.01% of the stock is currently owned by hedge funds and other institutional investors.
Several brokerages have issued reports on IQV. Wolfe Research initiated coverage on shares of Iqvia in a research report on Tuesday, April 2nd. They set a “market perform” rating for the company. Argus boosted their price objective on shares of Iqvia from $140.00 to $160.00 and gave the stock a “buy” rating in a report on Monday, February 25th. They noted that the move was a valuation call. Piper Jaffray Companies boosted their price objective on shares of Iqvia to $148.00 and gave the stock a “neutral” rating in a report on Friday, February 15th. Barclays restated a “buy” rating and issued a $155.00 price objective on shares of Iqvia in a report on Friday, February 15th. Finally, Wells Fargo & Co boosted their price objective on shares of Iqvia from $140.00 to $160.00 and gave the stock an “outperform” rating in a report on Tuesday, February 19th. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $146.88.
Iqvia (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 14th. The medical research company reported $1.50 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.47 by $0.03. The business had revenue of $2.69 billion for the quarter, compared to the consensus estimate of $2.62 billion. Iqvia had a net margin of 2.49% and a return on equity of 14.25%. The company’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.40 EPS. As a group, analysts anticipate that Iqvia Holdings Inc will post 5.87 EPS for the current year.
In other Iqvia news, Director Ronald A. Rittenmeyer sold 3,840 shares of the business’s stock in a transaction on Tuesday, February 5th. The shares were sold at an average price of $130.00, for a total transaction of $499,200.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Michael J. Evanisko sold 1,193 shares of the business’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $144.95, for a total transaction of $172,925.35. The disclosure for this sale can be found here. Over the last three months, insiders have sold 4,172,538 shares of company stock worth $587,465,163. Insiders own 6.00% of the company’s stock.
Iqvia Company Profile
IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Story: How to invest in blue-chip stocks
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.